HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback